You do not have permission to edit this page, for the following reason:
The action you have requested is limited to users in the group: Users.
== MitoEAGLE Inclusiveness Target Countries - Conference Grant ==
****: [[MitoEAGLE_Inclusiveness_Target_Countries#Conference_Grant_-_Grand_Period_3|Conference Grant Grand Period 3]]
::: '''[[Media:434_Scientific_report_ESCI_2018.pdf|Scientific report - ESCI2018]]'''
== MitoEAGLE Short-Term Scientific Mission ==
****: [[Short-Term_Scientific_Missions_MitoEAGLE#STSM_Grant_Period_3 |STSM Grant Period 3]]
::: '''Work Plan summary'''
:::: 1. The liver mitochondrial dysfunction plays an important role in the progression of non-alcoholic steatohepatitis, therefore improved protocols are required to evaluate mitochondrial fitness in the course of disease. Etomoxir is a well-known compound which irreversibly inhibits the carnitine palmitoyltransferase (CPT-1) in the outer surface of the mitochondrial inner membrane, therefore, blocks the transport of fatty acids into the mitochondrial matrix for further oxidation. However, among others we have shed light on the unspecific effect of etomoxir on the mitochondrial fatty acid oxidation (FAO; F-pathway linked respiration) in permeabilized Huh7 liver cells and mitochondria isolated from mouse liver. In our previous study (data not published) we have observed that the effect of etomoxir is concentration dependent. Low concentration (~40 µM) of etomoxir might inhibit NADH-linked respiration supported by glutamate or pyruvate plus malate. We have seen that high concentration of etomoxir (~200 µM) might block not only the NADH-linked pathway but also the Succinate-linked respiration.
:::: The aim of the secondment is to adjust the optimal etomoxir concentration which does not exert inhibitory effect towards other respiratory pathways and specifically blocks FAO on mitochondria.
:::: 2. The goal of this secondment is to provide standardized protocols to study FAO and to deepen our knowledge about the effect of etomoxir on F-pathway linked mitochondrial respiration and get rid of the artefacts created by overdosage of the inhibitor.
:::: Oroboros laboratory would provide a platform with its instrumental background, with its protocols, its experience and its international team to the objectives and aim of MitoEAGLE.
:::: 3. High-resolution Respirometry experiments will be performed on isolated mitochondria from mouse liver, heart and brain as well as permeabilized Huh7 liver cell lines. In order to detect FAO, we have used palmitoylcarnitine as source of fatty acid, which needs CPT-1 to enter the mitochondrial matrix and low concentration of malate supporting FAO. We also want to test other sources of fatty acid such as palmitoyl-CoA + carnitine + low amount of malate or palmitate + CoA + carnitine, which might influence the effect of etomoxir on CPT-1.
== Participated at ==
::::* [[MiPschool Coimbra 2019|MiP/MitoEAGLE Training School 2019 Coimbra PT]]
::::* [[ESCI 2019 Coimbra PT]]
::::* [[MitoEAGLE WG1 Coimbra 2019| MitoEAGLE WG1 2019 Coimbra PT]]
::::*[[MiP2018/MitoEAGLE Jurmala LV|MitoEAGLE 2018 Jurmala LV]]
::::* [[MiP2017/MitoEAGLE Hradec Kralove CZ|MitoEAGLE 2017 Hradec Kralove CZ]]
::::* [[IOC124|IOC124 Schroecken AT]]
== Visiting scientist in the Oroboros O2k-Laboratory ==
[[Pereira da Silva Grilo da Silva Filomena| Filomena Pereira da Silva Grilo da Silva]]: Visiting scientist at the [[Oroboros Laboratories: visiting scientists |Oroboros O2k-Laboratory]]
::::::* March 04 to March 22 2019
::::::* October 01 2016 to February 28 2017
Save page Show preview Show changes Cancel